Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Exploring new opportunities within the fast-growing market of microfluidics
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck has also decided to end the favezelimab clinical development program
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Aims to become India’s leading cancer testing company
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Subscribe To Our Newsletter & Stay Updated
